Didanosine

Didanosine

200px
200px
Systematic (IUPAC) name
9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3H-purin-6(9H)-one
Clinical data
AHFS/Drugs.com	monograph
MedlinePlus	a691006
Pregnancy category	AU: B2 US: B (No risk in non-human studies)
Legal status	UK: POM (Prescription only) US: ℞-only
Routes of administration	Oral
Pharmacokinetic data
Bioavailability	30 to 54%
Protein binding	Less than 5%
Biological half-life	1.5 hours
Excretion	Renal
Identifiers
CAS Number	69655-05-6 Y
ATC code	J05AF02 (WHO)
PubChem	CID: 50599
IUPHAR/BPS	4833
DrugBank	DB00900 Y
ChemSpider	45864 Y
UNII	K3GDH6OH08 Y
KEGG	D00296 Y
ChEBI	CHEBI:490877 Y
ChEMBL	CHEMBL1460 Y
NIAID ChemDB	000004
Chemical data
Formula	C10H12N4O3
Molecular mass	236.227 g/mol
SMILES O=C3/N=C\Nc1c3ncn1[C@@H]2O[C@@H](CC2)CO
InChI InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1 Y Key:BXZVVICBKDXVGW-NKWVEPMBSA-N Y
(verify)

Didanosine (2′,3′-dideoxyinosine, ddI, DDI) marketed under the trade names Videx and Videx EC. It is an antiretroviral medication used to treat HIV/AIDS in combination with other medications as part of highly active antiretroviral therapy (HAART). It is of the reverse transcriptase inhibitor class.

It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.

Adverse effects

The most common adverse events with didanosine are diarrhea, nausea, vomiting, abdominal pain, fever, headache and rash. Peripheral neuropathy occurred in 21-26% of participants in key didanosine trials.

Pancreatitis is rarely observed but has caused occasional fatalities, and has black box warning status. Other reported serious adverse events are retinal changes, optic neuritis and alterations of liver functions. The risk of some of these serious adverse events is increased by drinking alcohol.

In February 2010, the United States Food and Drug Administration issued a statement that patients using Didanosine (Videx) are at risk for a rare but potentially fatal liver disorder, non-cirrhotic portal hypertension.

Drug interactions

• A significant interaction has also been recorded with allopurinol, and administration of these drugs together should be avoided.
• Indinavir and delavirdine show reduced in plasma levels when administered simultaneously with didanosine; these drugs should be administered at different times.
• Ketoconazole, itraconazole, ciprofloxacin should be administered at a different time from didanosine due to interactions with the buffering agent.
• Administration with drugs with overlapping toxicity, such as zalcitabine and stavudine, is not recommended.
• Alcohol can exacerbate didanosine's toxicity, and avoiding drinking alcohol while taking didanosine is recommended.

Resistance

Drug resistance to didanosine does develop, though slower than to zidovudine (AZT). The most common mutation observed in vivo is L74V in the viral pol gene, which confers cross-resistance to zalcitabine; other mutations observed include K65R and M184V .

Mechanism of action

Didanosine (ddI) is a nucleoside analogue of adenosine. It differs from other nucleoside analogues, because it does not have any of the regular bases, instead it has hypoxanthine attached to the sugar ring. Within the cell, ddI is phosphorylated to the active metabolite of dideoxyadenosine triphosphate, ddATP, by cellular enzymes. Like other anti-HIV nucleoside analogs, it acts as a chain terminator by incorporation and inhibits viral reverse transcriptase by competing with natural dATP.

Pharmacokinetics

Oral absorption of didanosine is fairly low (42%) but rapid. Food substantially reduces didanosine bioavailability, and the drug should be administered on an empty stomach. The half-life in plasma is only 1.5 hours, but in the intracellular environment more than 12 hours. An enteric-coated formulation is now marketed as well. Elimination is predominantly renal; the kidneys actively secrete didanosine, the amount being 20% of the oral dose.

History

The related pro-drug of didanosine, 2′,3′-dideoxyadenosine (ddA), was initially synthesized by Morris J. Robins (professor of Organic Chemistry at Brigham Young University) and R.K. Robins in 1964. Subsequently, Samuel Broder, Hiroaki Mitsuya, and Robert Yarchoan in the National Cancer Institute (NCI) found that ddA and ddI could inhibit HIV replication in the test tube and conducted initial clinical trials showing that didanosine had activity in patients infected with HIV. On behalf of the NCI, they were awarded patents on these activities. Since the NCI does not market products directly, the National Institutes of Health (NIH) awarded a ten-year exclusive license to Bristol-Myers Squibb Co. (BMS) to market and sell ddI as Videx tablets.

Didanosine became the second drug approved for the treatment of HIV infection in many other countries, including in the United States by the Food and Drug Administration (FDA) on October 9, 1991. Its FDA approval helped bring down the price of zidovudine (AZT), the initial anti-HIV drug.

Didanosine has weak acid stability and is easily damaged by stomach acid. Therefore, the original formula approved by the FDA used chewable tablets that included an antacid buffering compound to neutralize stomach acid. The chewable tablets were not only large and fragile, they also were foul-tasting and the buffering compound would cause diarrhea. Although the FDA had not approved the original formulation for once-a-day dosing it was possible for some people to take it that way.

At the end of its ten-year license, BMS re-formulated Videx as Videx EC and patented that, which reformulation the FDA approved in 2000. The new formulation is a smaller capsule containing coated microspheres instead of using a buffering compound. It is approved by the FDA for once-a-day dosing. Also at the end of that ten-year period, the NIH licensed didanosine to Barr Laboratories under a non-exclusive license, and didanosine became the first generic anti-HIV drug marketed in the United States.

One of the patents for ddI expired in the United States on August 29, 2006, but other patents extend beyond that time.

Further reading

• Robins MJ, McCarthy JR Jr., Robins RJ. Biochemistry 1966; 5(1):224-31.
• Yarchoan R, Mitsuya H, Broder S. AIDS therapies. Sci Am 1988;259(4):110-9.
• Männistö P.T., Tuominen R.K. in Farmakologia ja Toksikologia, 5th edition: (ed. Koulu, Tuomisto, Paasonen) Medicina, 1996.
• Rang H.P., Dale M.M., Ritter J.M.: Pharmacology, 3rd edition. Pearson Professional Ltd, 1995.
• Watson et al.: Molecular Biology of the Gene 4^th edition. The Benjamin/Cummings Publishing Company, 1987.
• Mitsuya H, Yarchoan R, Broder S. Molecular targets for AIDS therapy. Science 1990;249(4976):1533-44.
• Yarchoan R, Mitsuya H, Thomas RV, et al. In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science 1989;245(4916):412-5.
• NIH Oral History of Samuel Broder describing development of AIDS drugs
• NIH Oral History of Robert Yarchoan describing development of AIDS drugs
• NIH Office of Technology Transfer Report on Development and Licensing of ddI
• FDA reviews safety of two HIV drugs